---
title: Medtronic (MDT)
layout: default
nav_order: 123
---

# Medtronic Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-yellow }

Pessimistic value: $120 B

Medtronic operates in the medical technology industry, specifically in the Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, Diabetes, and Neuromodulation segments. The company designs, manufactures, distributes, and sells a broad range of medical devices, therapies, and services worldwide.
{: .fs-6 .fw-300 }

---

{: .warning } 
>The moat rating and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.

**Business Overview:**

* **Revenue Distribution:** Medtronic's revenues are fairly evenly distributed across geographies. In fiscal 2023, the U.S. accounted for about 53% of revenue, and non-U.S. developed markets accounted for 35%. Revenues are well diversified among business units, with Cardiac and Vascular Group and Minimally Invasive Therapies Group representing over half of total sales in 2023.
* **Industry Trends:** The medical device market is characterized by rapid technological advancements, regulatory changes, increasing cost pressures, and an aging global population, which is driving demand for new treatments. The industry continues to consolidate as well, with large players seeking acquisitions to expand their market share and product offerings. This consolidation and increased competition put pressure on Medtronic to continuously innovate and offer a cost-effective portfolio of products.
* **Margins:** Medtronic has historically maintained strong profitability, with operating margins typically in the mid-20s. However, recent quarters have witnessed margin pressure due to pricing pressures in certain segments. While Medtronic aims to increase revenue growth, there may be a trade-off between increasing growth and maintaining higher margins. There was a 10% drop in its operating margin in 2020 and 2021 but the margin has mostly stabilized. 

**Moat Analysis:**

Medtronic's moat rating of 3/5 reflects a narrow moat stemming from a combination of factors:

1. **Switching Costs:** Medtronic benefits from moderately high switching costs, particularly in its implantable devices segment. Once a physician is trained on and comfortable using a specific Medtronic device, they are less likely to switch to a competitor's product due to the time and resources required to learn a new system. Additionally, hospitals have an incentive to standardize on a single supplier to streamline training, maintenance, and procurement, which further entrenches Medtronic's position. 
> {: .warning} However, these switching costs are not absolute, as new technologies and products from competitors can induce physicians and hospitals to change vendors.
2. **Intangible Assets:** Medtronic owns a large portfolio of patents, which offer some protection for its innovative products and technologies. However, as with any patent-driven moat, this strength has limitations. The average patent life is finite, and competitors can often design around existing patents with some effort.
3. **Economies of Scale:** Medtronic's large size enables it to invest heavily in research and development, creating a pipeline of new products. The company also benefits from scale in manufacturing and distribution, lowering costs relative to smaller competitors.
> {: .warning} However, the company has made a few acquisitions at extremely high premiums that are less likely to generate excess returns.

**Valuation:**

To arrive at a fair value for Medtronic, a discounted cash flow (DCF) model was used, focusing on free cash flow (FCF). A 10-year explicit forecast period, followed by a terminal value, was utilized. Key assumptions include:

* **Revenue Growth:** 2% annual growth rate for the first 5 years, assuming growth will stay in the low single digits.
* **Operating Margin:** We assume margins will revert to their long-term historical median of 25.4% by 2031. We acknowledge there is significant potential for expansion and improvement, but we are pessimistic given the pricing pressures in certain segments.
* **Reinvestment Rate:**  10% (consistent with Medtronic's historical reinvestment rate).
* **Cost of Capital (WACC):** 7.56% (using risk-free rate of 3.8%, equity risk premium of 5%, an estimated equity beta of 0.92, marginal tax rate of 19%, a pretax cost of debt of 4.27% and a target capital structure of 15% debt and 85% equity).

**Calculations:**

* **Terminal Value:** $553.573 billion (Using the key value driver formula with assumptions above)
* **Present Value of Operations:** $331.249 billion (Discounting projected free cash flows and terminal value at WACC)
* **Value of Nonoperating Assets:**  $7.762 billion (Based on the balance sheet)
* **Enterprise Value (EV):**  $339.011 billion (Operations + Nonoperating Assets)
* **Debt:** $44.436 billion (Based on the balance sheet)
* **Equity Value:** $294.575 billion (EV-Debt)
* **Number of Shares Outstanding:** 1.235 billion
* **Value per Share:** $238.43 (Equity Value/Shares Outstanding)

**Sensitivity Analysis and Scenarios:**

A sensitivity analysis was performed on key drivers (WACC, revenue growth, operating margin), which showed that valuation is sensitive to WACC and revenue growth assumptions, but not to operating margins.

In addition to the base-case, two additional scenarios were created:

* **Pessimistic:** This scenario assumes continued margin pressure and slower revenue growth than the base case. In this scenario, revenue grows at 1% over the explicit period, whereas margins increase gradually to 24%.
* **Optimistic:** Revenue grows at 3% with margins increasing to 26.4%.

The valuations from these two additional scenarios provided a range of $113 billion to $126 billion, with the base-case being in the middle.

**Conclusion:**

Based on the DCF model and sensitivity analysis, a conservative estimate of Medtronic's fair value is approximately $120 billion. While Medtronic's business fundamentals are decent, the increased competition, margin pressure, and uncertainties surrounding industry dynamics warrant a conservative approach to valuation. The current market valuation of $140 billion appears to be slightly rich, although not ridiculously so.

> {: .note} This valuation is based on the information available at the time of this analysis and is subject to change. It's important to note that valuations are inherently imprecise and should be used as a starting point for further investigation and not a definitive statement of a company's "true" value. Investors should undertake their own due diligence and formulate their own informed conclusions before making investment decisions.